Catalyst Reaches Enrollment Target for its U.S. Phase II Coc...( On behalf of everyone at Catalyst Pharm...),Health

Date:1/9/2009

"On behalf of everyone at Catalyst Pharmaceutical Partners, I would like to offer our sincere appreciation to the patients, their families, and all of the outstanding healthcare professionals who are participating in this trial," said Douglas Winship, Vice President of Regulatory Operations. "We look forward with great anticipation to the results of this landmark cocaine dependency trial and the opportunity to improve treatment outcomes of such patients everywhere."

About the Phase II Cocaine Trial

The Phase II trial is designed as a randomized, double-blind, placebo- controlled, intent-to-treat, multi-center trial to evaluate the safety and efficacy of CPP-109 as a treatment for cocaine addiction. Under the trial protocol, patients are being treated for a period of 12 weeks, with an additional 12 weeks of follow-up. The primary objective of the trial is to demonstrate that a larger proportion of CPP-109-treated subjects than placebo- treated subjects are cocaine-free during their last two weeks of treatment (weeks 11 and 12). Additionally, Catalyst intends to measure a number of secondary endpoints based on reductions of cocaine use and craving.

About Catalyst Pharmaceutical Partners

Catalyst Pharmaceutical Partners, Inc. is a biopharmaceutical company focused on the development and commercialization of prescription drugs for the treatment of addiction and obsessive-compulsive disorders. The Company has obtained from Brookhaven National Laboratory an exclusive worldwide license for Brookhaven's patent portfolio in the United States relating to the right to use vigabatrin to treat a wide variety of substance addictions and obsessive-compulsive disorders. Catalyst has also been granted rights to Brookhaven's vigabatrin-related foreign patents or patents pending in more than 30 countries. The Company's initial product candidate is CPP-109, which is Catalyst's version of vigabatrin. CP
'/>"/>

SOURCE Catalyst Pharmaceutical Partners, Inc. Copyright©2009 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3
Related medicine technology :

1. Catalyst Pharmaceutical Partners Announces Publication of Animal Data Demonstrating Vigabatrin Effective for Weight Loss
2. Catalyst Pharmaceutical Partners, Inc. Begins Enrollment for U.S. Phase II Clinical Trial of CPP-109 in Patients with Methamphetamine Addiction
3. Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
4. Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2007 Financial Results
5. Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction
6. AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108
7. Neurobiological Technologies Reaches Patient Enrollment Target For Interim Analysis of Viprinex(TM) Phase 3 Stroke Trials
8. Genmab Reaches Milestone in Ofatumumab Collaboration
9. CureHIV Reaches Out to Bill and Melinda Gates to Fund LiSAVIOR
10. Cancer Pioneer Reaches Key Agreement on Colon Cancer Drug OncoVAX(R)
11. CSL Behring Reaches Primary Endpoint in Clinical Study of C1-INH for Treatment of Hereditary Angioedema